# Iktos

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/iktos

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.iktos.ai
- Total disclosed funding: $16M
- Latest round: Series A (Mar 4, 2023)
- Investors on record: 3

## About

Based in Paris, France, and founded in 2016, Iktos provides artificial intelligence technology and software for ligand-based and structure-based de novo drug design. The company was co-founded by Yann Gaston-Mathe (CEO), Quentin Perron, and Nicolas Do Huu. In?February 2025,?Iktos SA received?EUR 2.5 million?in?grant?funding?from new investor European Innovation Council. The company offers deep learning-based de novo design for medicinal chemistry. Additionally, the firm has also developed Makya which is a SaaS application used for AI-driven de novo design. Furthermore, the also offers Spaya which is a computer-aided synthetic planning technology. Apart from this, Spaya API helps in assessing the synthetic feasibility of molecules. The company will use the February 2025 funding to boost its capabilities by integrating AI-driven molecular design, robotic synthesis, and biological testing.

## Funding rounds

- Series A, Mar 4, 2023, $16M — Omnes Capital, M Ventures, Debiopharm Innovation Fund

## Investors

- Omnes Capital (https://capitalatlas.ai/funds/omnes-capital) — Series A
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series A
- Debiopharm Innovation Fund (https://capitalatlas.ai/funds/debiopharm-innovation-fund) — Series A